Source:http://linkedlifedata.com/resource/pubmed/id/15036582
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-3-23
|
pubmed:abstractText |
Pharmacological characteristics of a serotonin (5-HT) and noradrenaline reuptake inhibitor (SNRI), milnacipran, in modulation of the synaptic plasticity were investigated. Milnacipran (30 mg/kg, i.p.) suppressed the long-term potentiation (LTP) in the hippocampal CA1 field of anesthetized rats. Milnacipran-induced suppression was reversed by pretreatment with the selective 5-HT1A receptor antagonist WAY 100635 (0.1 mg/kg, i.v.) or the alpha1-adrenoceptor antagonist prazosin (1 and 10 microg/rat, i.c.v.). The alpha2-adrenoceptor antagonist idazoxan (5 mg/kg, i.p.) did not influence the milnacipran-induced synaptic responses. These data suggest that the inhibitory effects of milnacipran on LTP induction are mediated via both 5-HT1A receptors and alpha1-adrenoceptors. In other words, functional interaction between the serotonergic and noradrenergic neuronal systems is involved in alteration of the hippocampal synaptic plasticity, which may be implicated in the SNRI-induced therapeutic effect on psychiatric disorders.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic Uptake Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclopropanes,
http://linkedlifedata.com/resource/pubmed/chemical/Norepinephrine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Serotonin, 5-HT1A,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, alpha-1,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/milnacipran
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0304-3940
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
357
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
91-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15036582-Adrenergic Uptake Inhibitors,
pubmed-meshheading:15036582-Animals,
pubmed-meshheading:15036582-Cyclopropanes,
pubmed-meshheading:15036582-Hippocampus,
pubmed-meshheading:15036582-Long-Term Potentiation,
pubmed-meshheading:15036582-Male,
pubmed-meshheading:15036582-Norepinephrine,
pubmed-meshheading:15036582-Rats,
pubmed-meshheading:15036582-Rats, Wistar,
pubmed-meshheading:15036582-Receptor, Serotonin, 5-HT1A,
pubmed-meshheading:15036582-Receptors, Adrenergic, alpha-1,
pubmed-meshheading:15036582-Serotonin Uptake Inhibitors
|
pubmed:year |
2004
|
pubmed:articleTitle |
Milnacipran, a serotonin and noradrenaline reuptake inhibitor, suppresses long-term potentiation in the rat hippocampal CA1 field via 5-HT1A receptors and alpha 1-adrenoceptors.
|
pubmed:affiliation |
Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|